TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04272164

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: technical taekwando training
Description: Light jogging followed by star jump, Different running styles (forward, backward and sideways), Stretching exercises (Upper and lower Limb), Pushups and sit ups, Punches (single, double, triple, nonstop punches including speed and power, punches with forward and backward stepping), Kicks (rising kick, front kick, middle kick, drop kick ( in +out+center), Stances (walk stance, punching stance, front deep stance, kicking stance), Blockings (solar block, upper block and lower block), Self -defense (neck gripping, hand gripping, locking), Sand bag drills, Balance training 10 repeatitions of 1 set each, 3 days a week for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: technical taekwando training
Description: Light jogging followed by star jump, Different running styles (forward, backward and sideways), Stretching exercises (Upper and lower Limb), Pushups and sit ups, Punches (single, double, triple, nonstop punches including speed and power, punches with forward and backward stepping), Kicks (rising kick, front kick, middle kick, drop kick ( in +out+center), Stances (walk stance, punching stance, front deep stance, kicking stance), Blockings (solar block, upper block and lower block), Self -defense (neck gripping, hand gripping, locking), Sand bag drills, Balance training 10 repeatitions of 1 set each, 3 days a week for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weighted rope jump training
Description: Basic bounce step with both feet 2. Bell jump with both feet 3. Skier's jump 4. Right foot skipping 5. Left foot skipping, 6. Alternate foot step 7. Boxer shuffle 8. Side straddle 9. Scissors 10. Bonus jump with both feet After the preparatory weighted rope jump training (WRJT) for 1 week, subjects in experimental group followed jumping training by repetition method 3 days in a week for 8 weeks in addition to the routine taekwondo training program. 3 sets per week with 30 seconds training duration and 30 seconds rest duration. with progressive increase in the intensity and no. of sets.
Study: NCT02568657

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Celox group

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bakri Balloon
Study: NCT00853489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: recombinant bone morphogenetic protein 2
Description: Patients will receive 1.50 mg/ml -12 mg of rhBMP-2 soaked on a absorbable collagen sponge (rhBMP-2/ACS) as an adjuvant to a freeze-dried cancellous allograft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous iliac crest bone graft
Description: Patients will undergo autogenous iliac crest bone graft surgery per the surgeon's usual practice.
Study: NCT02382341

Intervention type: DEVICE
Intervention: BIOSURE™ HEALICOIL™ PK Interference Screw
Description: Subjects will receive the appropriate sized BIOSURE™ HEALICOIL™ PK Interference Screw
Study: NCT02486952

Intervention type: DRUG
Intervention: Cyclophosphamide
Description: Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.

Intervention type: DRUG
Intervention: Hydroxydaunorubicin
Description: Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.

Intervention type: DRUG
Intervention: Oncovin
Description: Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.

Intervention type: DRUG
Intervention: Prednisone
Description: Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.

Intervention type: DRUG
Intervention: Rituximab
Description: Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
Study: NCT03102177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of stable Isotope labeled levothyroxine
Description: Administration of single dose of stable isotope carbon-13 labeled levothyroxine and measurement of blood levels of stable isotope-labeled levothyroxine
Study: NCT00638924

Intervention type: OTHER
Intervention: Shuttle walk test
Description: the test requires patients to walk at a gradually increasing speed, up and down a 10 m course identified by two marker cones, until they reach a symptom limited maximum. The walking speed was externally paced and controlled by a series of beeps played on a compact disk.
Study: NCT00237042

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self Management
Description: Two 1.5-hour in-person sessions and 6 10-15-minute telephone calls delivered by a dental hygienist, trained and supervised by a clinical psychologist. Structured, manual-based treatment based on standard cognitive-behavioral pain therapies and self-management interventions for chronic TMD pain. Sessions included education about the biopsychosocial model of chronic pain, TMD etiology and treatments, and the rationale for self-management; relaxation and stress management training; discussion of the role of stress and emotions as potential factors exacerbating and maintaining TMD symptoms; instruction and practice in self-monitoring of symptoms to identify factors that might be helpful to modify through self-care methods; practice of dentist-prescribed self-care treatments; and discussion of strategies to maintain gains and prevent relapse.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Self Management
Description: Self management as described above. However, the intervention also included education about the potential effects of hormones on TMD pain, instructions to monitor the association of pain and other symptoms with menstrual cycle changes, and planning for times in participants' menstrual cycles when symptoms might increase. Participant contacts were timed according to each participant's menstrual cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mcg ethinyl estradiol and 100 mcg levonorgestrel
Description: Combination pill (20 mcg ethinyl estradiol and 100 mcg levonorgestrel) taken daily for 6 months.
Study: NCT01045369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kaletra and Intelence Tablets
Description: Kaletra 400 mg twice a day and Intelence Tablets 200mg twice a day.
Study: NCT01913327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Week One, Risperidone 1 mg po qd; Week Two, 2 mg po qd; Week Three, 4 mg po qd; Week Four, 6 mg po qd; Week Five (and thereafter), 8 mg po qd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Single-dose 200 mg once orally, versus placebo single-dose, added-on to antipsychotic medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: Single-dose 200 mg once orally, versus placebo single-dose, added-on to antipsychotic medication.
Study: NCT02089217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Medical Management - no CAS
Description: Intensive Medical Management alone - no CAS
Study: NCT02441881

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venefit
Description: Endovenous radiofrequency device
Study: NCT05964894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ergonomic training
Description: ergonomic education \& exercise training
Study: NCT02971371

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lokomat
Description: Both the groups performed 40 45min Lokomat sessions, five times a week, between 9am and 11am. The RAGTand VR group received a visual feedback showing a VR run game where the patient had to collect or avoid objects, to motivate him/her to walk actively. Each avatar's leg movement corresponded to that performed by the patient. On the other hand, the RAGT without VR group was not provided an avatar, and a smile indicating the goodness of each leg movement. The biofeedback of the Lokomat gait orthosis is based on the interaction torques between the participant and the orthosis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Description: Both the groups performed 40 45min Lokomat sessions, five times a week, between 9am and 11am. The RAGTand VR group received a visual feedback showing a VR run game where the patient had to collect or avoid objects, to motivate him/her to walk actively. Each avatar's leg movement corresponded to that performed by the patient. On the other hand, the RAGT without VR group was not provided an avatar, and a smile indicating the goodness of each leg movement. The biofeedback of the Lokomat gait orthosis is based on the interaction torques between the participant and the orthosis
Study: NCT01627184

Intervention type: DEVICE
Intervention: Dexcom G4 CGM System
Study: NCT03899415

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCR redirected T cells
Description: HBV antigen specific TCR redirected T cell Infusions. Subjects will receive 1x10\^4 - 5x10\^6 TCR redirected T cells by IV infusion.
Study: NCT01987388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Exercise
Description: While in the calorimeter, each subject will complete four bouts of exercise. Each bout is approximately 5 minutes in duration at a predetermined speed and elevation to achieve an intensity of 85% of VO2 max according to their fitness level test described previously. Subjects then sit quietly until either the next meal or the next exercise bout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Exercise
Description: While in the calorimeter, each subject will complete four bouts of exercise. Each bout is approximately 5 minutes in duration at a predetermined speed and elevation to achieve an intensity of 85% of VO2 max according to their fitness level test described previously. Subjects then sit quietly until either the next meal or the next exercise bout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Intensity Exercise
Description: While in the calorimeter, each subject completes one exercise bout approximately 40 minutes in duration, at a predetermined speed and elevation, to achieve an intensity of 65% of VO2 max. Subjects then sit quietly until the next meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Intensity Exercise
Description: While in the calorimeter, each subject completes one exercise bout approximately 40 minutes in duration, at a predetermined speed and elevation, to achieve an intensity of 65% of VO2 max. Subjects then sit quietly until the next meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Carbohydrate Beverage
Description: Participants will consume a high carbohydrate beverage (750 g) with the following composition: 2.13 MJ/d, 113g carbohydrate, 4g fat, 6g protein.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Carbohydrate Beverage
Description: Participants will consume a high carbohydrate beverage (750 g) with the following composition: 2.13 MJ/d, 113g carbohydrate, 4g fat, 6g protein.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fat Beverage
Description: Participants will consume a high fat beverage (750 g) with the following composition: 2.11 MJ/d, 8g carbohydrate, 50g fat, 7g protein.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fat Beverage
Description: Participants will consume a high fat beverage (750 g) with the following composition: 2.11 MJ/d, 8g carbohydrate, 50g fat, 7g protein.
Study: NCT03435263

Intervention type: OTHER
Intervention: home management
Description: pregnant women presented with PROM will be randomized into 2 groups group a will be discharged home after initial assessment and group B will be admitted to hospital as usual
Study: NCT03493139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Across the Curriculum
Description: Activity breaks will be designed for delivery in the classroom without reconfiguration of the classroom space. Activities will emphasize whole body movements, using large muscle groups. Each break includes multiple activities. Each activity lasts about 2 minutes. There will be a total of about 20 minutes of physical activity done each school day.
Study: NCT03801941

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wearing ATLAS device during evaluation at 5th day
Description: Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities without ATLAS Device at the 4th or 5th day of a 4 weeks rehabilitation program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wearing ATLAS device during evaluation at 5th day
Description: Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities without ATLAS Device at the 4th or 5th day of a 4 weeks rehabilitation program.
Study: NCT01543555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 80mg anytime within 18 hours before surgery. A postoperative 40mg atorvastatin dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg atorvastatin daily for the next seven days.
Study: NCT04587453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the immunoglobulin G4 subclass that specifically binds to human interleukin-13 (IL-13) and blocks the interaction with IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains the same excipients in the same concentration only lacking tralokinumab.
Study: NCT04587453

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Topical corticosteroids (TCS)
Description: TCS administered as needed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (TCS)
Description: TCS administered as needed.
Study: NCT03337139

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gold Standard Behavior Therapy for Weight Loss
Description: Group-based behavioral treatment for weight loss, with a standard emphasis on diet (65% of session) and physical activity goals (25% of session). Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session). Participants will be asked to utilize digital monitoring devices for physical activity, weight, and diet. Coaches will not have access to the digital data that participants provide on physical activity, weight, and diet monitoring devices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gold Standard Behavior Therapy for Weight Loss
Description: Group-based behavioral treatment for weight loss, with a standard emphasis on diet (65% of session) and physical activity goals (25% of session). Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session). Participants will be asked to utilize digital monitoring devices for physical activity, weight, and diet. Coaches will not have access to the digital data that participants provide on physical activity, weight, and diet monitoring devices.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Remote Behavior Therapy for Weight Loss
Description: Individual, monthly, brief phone calls with coach and weekly text messages. The content of these calls and messages will be determined by participant self-report. Coaches will not have access to the digital data that participants provide on physical activity, weight, and diet monitoring devices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Data Sharing Behavior Therapy for Weight Loss
Description: Individual, monthly, brief phone calls with coach and weekly text messages. The content of these calls and messages will be determined by the digital data that has been shared with the coach from physical activity, weight, and diet monitoring devices.
Study: NCT02245451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Study: NCT01543555

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo 80mg anytime within 18 hours before surgery. A postoperative 40mg matching placebo dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg placebo daily for the next seven days.
Study: NCT04539626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen Therapy
Description: EVRA skin patches with norelgesetromin 6mg / ethinyl estradiol 0.60mg, (1 patch will be placed every week during 21 days)
Study: NCT02172092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SodiumChloride
Description: Infusion of SodiumChloride, blood samples to calculate extracellular volume.
Study: NCT01536002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Intravenous infusion over 30 min of Propofol 3-4 mg/kg body weight
Study: NCT01814683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: 14 days of supervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: 7 days of supervised primaquine (7mg/kg total dose) administered once per day (1.0 mg/kg OD) followed by 7 days of placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 14 days placebo.
Study: NCT00111475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Administered by subcutaneous injection
Study: NCT04128202

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sunnyside
Description: The Sunnyside intervention is an online intervention (an interactive website with didactic material and interactive tools) targeting skills to manage mood during and after pregnancy. The Sunnyside intervention will consist of 6weeks of online lessons during pregnancy and booster sessions at 2 weeks, 4 weeks, and 6 weeks postpartum. Each lesson takes approximately 10 minutes to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sunnyside Plus
Description: Sunnyside Plus will build upon the Sunnyside intervention, plus include additional education and support to promote breastfeeding. Breastfeeding education and skills will be provided during the 6weeks of online lessons during pregnancy; each lesson takes approximately 10 minutes to complete. Breastfeeding support will continue through 6 weeks postpartum. This postpartum support will involve weekly online lessons(each taking approximately 10 minutes to complete), text support messages(3 sent during weeks 1 and 2, 2 sent during weeks 3 and 4, 1 sent during weeks 5 and 6), and video support calls with a Lactation Educator (LE)provided on an as-needed basis(exception: at least 1 video call is required during both week 1 postpartum and week 2 postpartum).
Study: NCT02382926

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capacitive ECG and contactless heart and breathing rate measurements via camera
Description: During a 30 minute driving simulation cardiologic patients in rehabilitation undergo capacitive ECG measurements via sensors in the car seat as well as heart and breathing rate measurements via camera according to the Eulerian Magnification Method.
Study: NCT00111475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Administered by subcutaneous injection
Study: NCT01690975

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - single dose at start of each treatment period
Study: NCT00111475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study: NCT03051087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganirelix acetate
Study: NCT01784952

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: The intervention program consisted of replacing of refined rice intake with 1/3 of legumes, 1/3 of barleys, and 1/3 of whole grains three times per day as a high carbohydrate source and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake. The subjects were recommended to drink no more than one alcoholic beverage drink (15 g alcohol) per day and were assigned physical activity consisting of a regular 30-min walk after dinner each day. Participants were also instructed to record their physical activity diary for 24 h every 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary intervention
Description: The intervention program consisted of replacing of refined rice intake with 1/3 of legumes, 1/3 of barleys, and 1/3 of whole grains three times per day as a high carbohydrate source and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake. The subjects were recommended to drink no more than one alcoholic beverage drink (15 g alcohol) per day and were assigned physical activity consisting of a regular 30-min walk after dinner each day. Participants were also instructed to record their physical activity diary for 24 h every 4 weeks.
Study: NCT02731807

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose A: TA-65 24mg, powder

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose A: TA-65 24mg, powder
Study: NCT01690975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzonatate - 400 mg
Description: Benzonatate - 400 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzonatate - 600 mg
Description: Benzonatate - 600 mg single dose
Study: NCT01111214

Intervention type: OTHER
Intervention: no intervention
Description: There is no intervention. This is a non interventional study.